Leading global medical affairs strategy and execution for Secukinumab in immunology, overseeing scientific integrity, GCP adherence, safety design, and a multi-billion dollar business.

Global leadership for medical affairs strategy across autoinflammatory diseases and ocular gene therapy, delivering go-to-market and development plans.

Established and led the New Brand Medical Incubator Europe and Rare Disease Unit, with direct and matrix leadership of ~50 colleagues and responsibility for product launches including ULTIBRO, BROLUCIZUMAB and COSENTYX dermatology indication.

Strategic medical leadership for ophthalmology franchise in Europe, including scientific partnerships, publications and global launch activities.

Leadership of European medical franchise with responsibility for strategy, affiliate support and excellence in execution.

Medical leadership for European primary care franchise, driving strategic alignment and operational excellence.

Worldwide leadership for PRADAXA launch in pVTEp, SPAF and VTEt indications, global registration strategy, building a 13-person global medical affairs team and co-chairing pharmacovigilance working group.

Initiated antidote development for PRADAXA and authored multiple peer-reviewed publications and guidelines on bleeding emergencies, dialysis and intoxication management.

Developed clinical development plan for TWYNSTA and global submission strategy for PRADAXA in core cardiovascular indications.

Supported local launches of EXUBERA and SOMAVERT and provided medical expertise across cardiology, endocrinology and diabetes.

Clinical training in gastroenterology and diabetes as part of medical doctor residency.

Clinical training in endocrinology.

Clinical training in pathology.

Internship and first year residency in internal medicine.